BriaCell Therapeutics Corp. BCTX
3.68 USD +0.01 (+0.27%)
Nov 11, 2026, 1:19 PM EST
3.59 Day range 3.75
2.60 52-week range 13.09
- YTD
- -48.24%
- 1 year
- -65.09%
News
defenseworld.net Briacell Therap (NASDAQ:BCTX) Shares Break Above 200 Day Moving Average – Should You Sell? Shares of Briacell Therap (NASDAQ: BCTX - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $3.79 and traded as high as…
globenewswire.com BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 PHILADELPHIA and VANCOUVER, British Columbia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Awarded 2026 “Immunotherapy Solution of the Year” By BioTech Breakthrough LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 28.9% to $4.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.2 million. Valion Bio (NASDAQ:VBIO)…
benzinga.com Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" PHILADELPHIA and…
benzinga.com BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone Cell-based immunotherapy program is designed to harness patients’ own immune systemsBria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific…
benzinga.com BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation…
benzinga.com Odette Cancer Centre At Sunnybrook Health Sciences Centre Joined BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured…- benzinga.com BriaCell Therapeutics Enters Manufacturing Arrangement With FUJIFILM Biotechnologies To Support Phase 3 Clinical Development And Potential Future Commercial Supply Of Its Allogenic Cell Therapy BRIA-IMT Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (ClinicalTrials.gov…
- benzinga.com BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today
- benzinga.com BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle Technology For Intradermal Administration Of BriaCell’s Bria-IMT BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has entered
benzinga.com BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY BriaCell Therapeutics (NASDAQ:BCTX) reported quarterly losses of $(0.99) per share. This is a 93.96 percent increase over losses of $(16.40) per share from the same period last year.- benzinga.com Reported Earlier, Cancer Drug Developer BriaCell Prices $4.7M Stock Offering Of 1.45M Shares At $3.25/Share to Fund Operations and Research BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care,…
benzinga.com BriaCell Therapeutics Receives Sixth Positive Recommendation From Independent Data Safety Monitoring Board For Its Pivotal Phase 3 Bria-ABC Trial Of Bria-IMT Plus Immune Checkpoint Inhibitor BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces…
benzinga.com BriaCell Therapeutics Presents Positive Clinical Data From Three Clinical Data Poster Presentations, Three Publication-Only Abstracts At 2026 ASCO Annual Meeting BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased…
benzinga.com BriaCell Therapeutics Announces Progress In Developing Bria-OVA+, Next Gen, Personalized, Off-The-Shelf, Cell-Based Immunotherapy For Ovarian Cancer BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer,…- benzinga.com BriaCell Therapeutics Completes Manufacturing Clinical Supplies Of Bria-PROS+ For Prostate Cancer BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces…
- benzinga.com BriaCell Therapeutics Adds Penn Medicine's Abramson Cancer Center As Clinical Trial Site In BriaCell's Ongoing Pivotal Phase 3 Clinical Study Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida,…
- benzinga.com BriaCell Therapeutics\ Pivotal Phase 3 Bria-ABC Trial Enrolls 230 Participants BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces…
- benzinga.com BriaCell Therapeutics Receives FDA Clearance To Initiate Clinical Evaluation Of Bria-BRES+, Its Next Generation Cell-Based Immunotherapy For Metastatic Breast Cancer FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation…
- benzinga.com BriaCell Therapeutics Presents Data From Preclinical Bria-OTS+ Platform At 2026 AACR Annual Meeting Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line modelsImmune cells activated by Bria-OTS+ exhibit serial killing activity…
- benzinga.com BriaCell Therapeutics Presents One Poster Featuring Data From Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor, And Two Posters Highlighting Further Analyses Of Phase 2 Data At 2026 AACR Annual Meeting Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification…
- benzinga.com BriaCell Therapeutics To Present Four Posters At 2026 American Association For Cancer Research Annual Meeting BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces…
- benzinga.com BriaCell Secures Prime Spotlight at Major 2026 Cancer Conference to Reveal 'Next-Gen' Personalized Immunotherapy Progress BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today…
benzinga.com BriaCell Therapeutics And BriaPro Therapeutics Enter Into A Definitive Purchase Agreement Pursuant To Which BriaPro Has Agreed To Purchase BriaCell's Exclusive License To Develop And Commercialize Soluble CD80 As A Biologic Agent For The Treatment Of Cancer And Other Associated Assets BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL))) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its…- benzinga.com BriaCell Phase 3 Breast Cancer Trial Clears Fifth Straight Safety Review, Study Continues BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company"), clinical-stage biotechnology company developing novel immunotherapies to transform cancer…
- benzinga.com BriaCell Therapeutics Announces Data From Phase 2 Trial Evaluating Participants Surpassing Expected Benchmarks For Metastatic Breast Cancer BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer…
benzinga.com Is the Market Bullish or Bearish on BriaCell Therapeutics Corp? 
benzinga.com Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Nasdaq Falls Over 100 Points; Bank of America Posts Upbeat Earnings 
benzinga.com Glaukos, Trip.com Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com What's Going On With BriaCell Therapeutics Stock Wednesday? BriaCell Therapeutics stock surges with positive news of patient's complete resolution of lung metastasis in Bria-OTS study.
benzinga.com Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket - benzinga.com Reported Earlier, BriaCell Therapeutics Prices $30M Public Offering Of 5,366,726 Units At $5.59 Per Unit To Fund Working Capital And Advance Immunotherapy Programs Each Warrant is immediately exercisable, will entitle the holder to purchase one common share at an exercise price of $6.93 per share and will expire five years from the date of issuance.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com BriaCell Therapeutics Announces Complete Resolution Of Lung Metastasis In Patient With Metastatic Breast Cancer Treated With Bria-OTS, Personalized Off The Shelf Immunotherapy BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care,…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com BriaCell Therapeutics Publishes Phase 3 Bria-IMT Clinical Study In Metastatic Breast Cancer BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased…
- benzinga.com BriaCell Shares Survival And Biomarker Results For Breast Cancer Therapy At Major San Antonio Conference BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,…
benzinga.com Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - benzinga.com BriaCell Therapeutics To Present Phase 2 Survival, And Phase 3 Biomarker Data Across Three Clinical Posters At 2025 SABCS Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2,…
- benzinga.com BriaCell Therapeutics To Highlight Phase 2 Safety And Efficacy Signals And Biomarker Findings In Both Phase 2 And Pivotal Phase 3 Studies At 2025 SABCS Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase…
- benzinga.com BriaCell Therapeutics' Unit Partners With Research.AI To Design Anti-Cancer Isoform-selective Kinase Inhibitors BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,…
- benzinga.com BriaCell Therapeutics To Present Three Clinical, One Preclinical Posters At 2025 San Antonio Breast Cancer Symposium BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is…
- benzinga.com BriaCell Therapeutics Presents Evidence Of Strong Immune System Engagement And Anti-Cancer Activity Of Next-Gen Bria-OTS+ Platform In Preclinical Models At SITC Annual Meeting Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responsesIncreased tumor cell cytotoxicity induced by both…
- benzinga.com BriaCell To Present Preclinical Data On Next-Gen Cancer Vaccine Platform At SITC 2025 BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,…
- benzinga.com The Independent Data Safety Monitoring Board Has Issued Its Fourth Consecutive Positive Recommendation Following Review Of Safety Data From BriaCell Therapeutics' Phase 3 Study Of Bria-IMT Plus An Immune Checkpoint Inhibitor For Metastatic Breast Cancer Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell's…